MX2018010445A - Anticuerpos especificos del receptor de poliovirus humano (rvp). - Google Patents
Anticuerpos especificos del receptor de poliovirus humano (rvp).Info
- Publication number
- MX2018010445A MX2018010445A MX2018010445A MX2018010445A MX2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A
- Authority
- MX
- Mexico
- Prior art keywords
- pvr
- antibodies specific
- poliovirus receptor
- human poliovirus
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301727P | 2016-03-01 | 2016-03-01 | |
| US201662364924P | 2016-07-21 | 2016-07-21 | |
| PCT/IL2017/050256 WO2017149538A1 (en) | 2016-03-01 | 2017-02-28 | Antibodies specific to human poliovirus receptor (pvr) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010445A true MX2018010445A (es) | 2019-10-17 |
Family
ID=58410405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010445A MX2018010445A (es) | 2016-03-01 | 2017-02-28 | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
| MX2022014867A MX2022014867A (es) | 2016-03-01 | 2018-08-29 | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014867A MX2022014867A (es) | 2016-03-01 | 2018-08-29 | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10906987B2 (enExample) |
| EP (2) | EP4043492A1 (enExample) |
| JP (1) | JP6966176B2 (enExample) |
| KR (2) | KR102812377B1 (enExample) |
| CN (1) | CN109071666B (enExample) |
| AU (2) | AU2017228055B2 (enExample) |
| BR (1) | BR112018067522A2 (enExample) |
| CA (1) | CA3015619A1 (enExample) |
| CO (1) | CO2018010538A2 (enExample) |
| ES (1) | ES2903280T3 (enExample) |
| IL (2) | IL296874A (enExample) |
| MX (2) | MX2018010445A (enExample) |
| RU (1) | RU2756275C2 (enExample) |
| SG (1) | SG11201807437XA (enExample) |
| WO (1) | WO2017149538A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11098130B1 (en) | 2015-08-03 | 2021-08-24 | Tasrif Pharmaceutical, LLC | Antibodies and antibody fragments against the CD155 receptor and methods of use thereof |
| CN109071666B (zh) | 2016-03-01 | 2022-06-28 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 人脊髓灰质炎病毒受体(pvr)特异性抗体 |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| WO2019102456A1 (en) | 2017-11-27 | 2019-05-31 | University Of Rijeka Faculty Of Medicine | Immunotoxins for treating cancer |
| CA3097679A1 (en) | 2018-05-09 | 2019-11-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human nectin4 |
| TW202023625A (zh) | 2018-08-23 | 2020-07-01 | 美商西雅圖遺傳學公司 | 抗tigit抗體 |
| WO2020047473A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| KR20250160211A (ko) | 2018-08-30 | 2025-11-11 | 이뮤니티바이오, 인크. | 다중-사슬 키메라 폴리펩타이드 및 이의 용도 |
| CN113365663B (zh) | 2018-08-30 | 2025-11-21 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| JP7606706B2 (ja) * | 2019-01-13 | 2024-12-26 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． | ヒトネクチン－２に特異的な抗体 |
| AU2020294797B2 (en) | 2019-06-21 | 2025-12-18 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| JP7754506B2 (ja) | 2019-10-08 | 2025-10-15 | ネクチン セラピューティクス エルティーディー． | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 |
| KR102370915B1 (ko) | 2019-10-22 | 2022-03-08 | 단국대학교 천안캠퍼스 산학협력단 | 폴리오바이러스를 검출하기 위한 등온증폭 반응용 프라이머 세트 및 이의 용도 |
| AU2021219720B2 (en) | 2020-02-11 | 2025-10-02 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| JP2023513573A (ja) | 2020-02-11 | 2023-03-31 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢性および炎症性疾患を治療する方法 |
| US12497462B2 (en) | 2020-04-29 | 2025-12-16 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| WO2021247604A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| CN112538108B (zh) * | 2020-12-24 | 2022-06-28 | 郑州大学 | 高亲和pvr突变体 |
| JP2024531426A (ja) * | 2021-08-20 | 2024-08-29 | タスリフ ファーマシューティカル，エルエルシー | Ｃｄ１５５に対する抗体および抗原結合フラグメント、その使用方法 |
| CN114005538B (zh) * | 2021-11-30 | 2025-10-28 | 中国医科大学附属第一医院 | Nectin家族和类nectin分子在低级别胶质瘤预后模型中的应用 |
| EP4486368A1 (en) | 2022-03-02 | 2025-01-08 | ImmunityBio, Inc. | Method of treating pancreatic cancer |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| CA3261618A1 (en) | 2022-09-04 | 2024-03-07 | Nectin Therapeutics Ltd. | Humanized Anti-PVR Antibody Drug Conjugates |
| CN116284395B (zh) * | 2022-12-12 | 2024-11-08 | 合肥天港免疫药物有限公司 | 抗cd155的抗体及其应用 |
| WO2024233945A1 (en) * | 2023-05-10 | 2024-11-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy of polio virus receptor inhibitors and fucose |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| KR102669477B1 (ko) * | 2023-09-04 | 2024-06-10 | 재단법인 아산사회복지재단 | 신규 항-pvr 항체 또는 이의 항원 결합 단편, 및 이의 용도 |
| CN118359711B (zh) * | 2024-06-20 | 2024-10-15 | 华淞(上海)生物医药科技有限公司 | 一种抗脊髓灰质炎病毒1型抗体及其制备方法和用途 |
| WO2026043906A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| US20260049118A1 (en) | 2024-08-19 | 2026-02-19 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| JP3490437B2 (ja) | 1992-01-23 | 2004-01-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 単量体および二量体抗体フラグメント融合タンパク質 |
| ATE348175T1 (de) | 1992-07-17 | 2007-01-15 | Dana Farber Cancer Inst Inc | Method eder intrazellularen bindung von zielgerichteten molekülen |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| EP0721350A4 (en) | 1993-07-30 | 1999-08-11 | Univ Jefferson | INTRACELLULAR IMMUNIZATION |
| WO1996013583A2 (en) | 1994-10-20 | 1996-05-09 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DE69633175T2 (de) | 1995-05-23 | 2005-08-11 | Morphosys Ag | Multimere proteine |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| US6518033B1 (en) * | 1998-08-05 | 2003-02-11 | The Research Foundation Of State University Of New York | Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment |
| US6264940B1 (en) * | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
| US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| ATE535258T1 (de) | 2001-06-01 | 2011-12-15 | Cornell Res Foundation Inc | Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen |
| US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| ES2609429T3 (es) | 2005-05-12 | 2017-04-20 | Zymogenetics, Inc. | Composiciones y métodos para modular respuestas inmunitarias |
| JP5457671B2 (ja) | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用 |
| MX2008007682A (es) | 2005-12-20 | 2008-10-23 | Sbi Biotech Co Ltd | Anticuerpo anti-ilt7. |
| AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| FR2909092B1 (fr) | 2006-11-24 | 2012-10-19 | Pf Medicament | Nouveaux anticorps anti-proliferation |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| HUE036780T2 (hu) | 2008-04-09 | 2018-07-30 | Genentech Inc | Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére |
| JP5686361B2 (ja) * | 2010-01-28 | 2015-03-18 | 国立大学法人 筑波大学 | 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法 |
| MX356400B (es) | 2010-12-08 | 2018-05-28 | Abbvie Stemcentrx Llc | Moduladores novedosos y metodos de uso. |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| EP3401329A1 (en) | 2011-07-15 | 2018-11-14 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| PL2800196T3 (pl) | 2011-12-27 | 2019-05-31 | Lg Chemical Ltd | Litowa bateria akumulatorowa i sposób jej wytwarzania |
| JP2015520192A (ja) | 2012-06-06 | 2015-07-16 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｈｉｐｐｏ経路を調節する結合剤およびその使用 |
| KR20150090919A (ko) | 2012-12-04 | 2015-08-06 | 온코메드 파마슈티칼스, 인크. | 결합제를 사용한 면역요법 |
| RU2019109456A (ru) | 2013-02-22 | 2019-04-10 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые конъюгаты антител и их применения |
| AU2014290069B2 (en) * | 2013-07-16 | 2019-01-03 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
| KR20160047567A (ko) | 2013-08-28 | 2016-05-02 | 스템센트알엑스 인코포레이티드 | 조작된 항-dll3 접합체 및 사용 방법 |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| US20170013850A1 (en) | 2014-03-18 | 2017-01-19 | Vural Gokmen | A solution for extending shelf life of ready-to-eat fresh fruits and/or vegetables and an application method thereof |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| CN109071666B (zh) | 2016-03-01 | 2022-06-28 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 人脊髓灰质炎病毒受体(pvr)特异性抗体 |
-
2017
- 2017-02-28 CN CN201780027236.6A patent/CN109071666B/zh active Active
- 2017-02-28 IL IL296874A patent/IL296874A/en unknown
- 2017-02-28 AU AU2017228055A patent/AU2017228055B2/en active Active
- 2017-02-28 WO PCT/IL2017/050256 patent/WO2017149538A1/en not_active Ceased
- 2017-02-28 EP EP21200696.9A patent/EP4043492A1/en active Pending
- 2017-02-28 RU RU2018134065A patent/RU2756275C2/ru active
- 2017-02-28 KR KR1020187028157A patent/KR102812377B1/ko active Active
- 2017-02-28 US US16/081,667 patent/US10906987B2/en active Active
- 2017-02-28 CA CA3015619A patent/CA3015619A1/en active Pending
- 2017-02-28 ES ES17713469T patent/ES2903280T3/es active Active
- 2017-02-28 KR KR1020257014225A patent/KR20250065434A/ko active Pending
- 2017-02-28 JP JP2018544355A patent/JP6966176B2/ja active Active
- 2017-02-28 SG SG11201807437XA patent/SG11201807437XA/en unknown
- 2017-02-28 MX MX2018010445A patent/MX2018010445A/es unknown
- 2017-02-28 EP EP17713469.9A patent/EP3423495B1/en active Active
- 2017-02-28 IL IL261200A patent/IL261200B2/en unknown
- 2017-02-28 BR BR112018067522-9A patent/BR112018067522A2/pt active IP Right Grant
-
2018
- 2018-08-29 MX MX2022014867A patent/MX2022014867A/es unknown
- 2018-10-01 CO CONC2018/0010538A patent/CO2018010538A2/es unknown
-
2020
- 2020-12-10 US US17/118,062 patent/US20210115150A1/en not_active Abandoned
-
2023
- 2023-08-15 US US18/450,022 patent/US20240018257A1/en active Pending
-
2024
- 2024-03-25 AU AU2024201912A patent/AU2024201912A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017228055B2 (en) | 2024-04-04 |
| RU2018134065A (ru) | 2020-04-01 |
| BR112018067522A2 (pt) | 2019-02-05 |
| CO2018010538A2 (es) | 2018-12-14 |
| US20240018257A1 (en) | 2024-01-18 |
| AU2024201912A1 (en) | 2024-04-11 |
| KR20180133399A (ko) | 2018-12-14 |
| IL261200B (en) | 2022-11-01 |
| KR102812377B1 (ko) | 2025-05-23 |
| CN109071666A (zh) | 2018-12-21 |
| MX2022014867A (es) | 2023-03-06 |
| EP3423495A1 (en) | 2019-01-09 |
| ES2903280T3 (es) | 2022-03-31 |
| CA3015619A1 (en) | 2017-09-08 |
| US10906987B2 (en) | 2021-02-02 |
| CN109071666B (zh) | 2022-06-28 |
| IL261200B2 (en) | 2023-03-01 |
| IL296874A (en) | 2022-11-01 |
| JP6966176B2 (ja) | 2021-11-10 |
| JP2019511212A (ja) | 2019-04-25 |
| US20200040092A1 (en) | 2020-02-06 |
| KR20250065434A (ko) | 2025-05-12 |
| SG11201807437XA (en) | 2018-09-27 |
| WO2017149538A1 (en) | 2017-09-08 |
| EP3423495B1 (en) | 2021-10-20 |
| EP4043492A1 (en) | 2022-08-17 |
| AU2017228055A1 (en) | 2018-09-20 |
| NZ745564A (en) | 2024-12-20 |
| IL261200A (en) | 2018-10-31 |
| US20210115150A1 (en) | 2021-04-22 |
| RU2018134065A3 (enExample) | 2020-07-20 |
| RU2756275C2 (ru) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010445A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| ECSP19072235A (es) | Anticuerpos anti-ILT4 y fragmentos de unión a antígeno | |
| CY1121539T1 (el) | Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων | |
| BR112016014731A2 (pt) | Anticorpos anti-baff | |
| CL2018000378A1 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos | |
| CL2018000744A1 (es) | Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso. | |
| CO2018000244A2 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| CO2018011804A2 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos | |
| DOP2019000165A (es) | Anticuerpos anti-ox40 y sus usos | |
| MX2016010856A (es) | Metodo. | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
| MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
| MX2017001597A (es) | Anticuerpos anti-pd-l1. | |
| ECSP17012781A (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
| BR112018014016A2 (pt) | combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer | |
| BR112017011914A2 (pt) | ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso? | |
| BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
| MX377753B (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos | |
| CL2019003557A1 (es) | Anticuerpos anti-trkb. | |
| BR112019020412A2 (pt) | composições e métodos para detectar câncer de pulmão | |
| AR099899A1 (es) | Anticuerpos y fragmentos anti-vista | |
| BR112017020894A2 (pt) | imunoreceptores específicos claudina-18.2 e epítopos de células t | |
| MA41016B1 (fr) | Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20 |